Document Detail


Titanium-nitride-oxide-coated Titan-2 bioactive coronary stent: a new breakthrough in interventional cardiology.
MedLine Citation:
PMID:  21983305     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
The introduction of drug-eluting stents (DES) has revolutionized the field of interventional cardiology, since it has reduced the incidence of restenosis by 50% to 70%. However, recent worrisome data from registries and meta-analyses emphasized higher rates of late and very late stent thrombosis associated with DES. The recently introduced titanium-nitride-oxide-coated stent bioactive stent (Titan-2) was manufactured by a proprietary process to coat titanium-nitride-oxide on the surface of the stainless steel stent, based on a plasma technology using the nano-synthesis of gas and metal. This late-breaking stent has demonstrated an excellent biocompatibility, as reflected by lower rates of platelet aggregation and fibrin deposition, and better endothelialization. Preclinical and clinical trials and registries involving real-life unselected populations have shown a low rate of major adverse cardiac events at long-term follow-up. Restenosis rates were comparable with those of DES, with very rare stent thrombosis. Equally favorable results have been obtained in patients at high-risk of in-stent restenosis, such as diabetics and those with small coronary arteries. Results in patients presenting with acute coronary syndrome have been again comparable to those of DES, with tendency to lower rates of myocardial infarction and stent thrombosis. Comparisons with second generation drug-eluting stents have also been promising.
Authors:
P Karjalainen; W Nammas
Related Documents :
2885105 - Alpha 1-adrenoceptor activity regulates release of adenosine from the ischemic myocardi...
22527025 - Tendency of mortality in acute myocardial infarction in curitiba (pr) in the period of ...
3121675 - Responses of coronary arteries of cardiac transplant patients to acetylcholine.
1719435 - On-line measurement of nitric oxide release from organic nitrates in the intact coronar...
15772335 - A novel hemoglobin-based blood substitute protects against myocardial reperfusion injury.
11303005 - A cardiac prevention and rehabilitation programme for all patients at first presentatio...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Minerva cardioangiologica     Volume:  59     ISSN:  0026-4725     ISO Abbreviation:  Minerva Cardioangiol     Publication Date:  2011 Oct 
Date Detail:
Created Date:  2011-10-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0400725     Medline TA:  Minerva Cardioangiol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  447-54     Citation Subset:  IM    
Affiliation:
Heart Center, Satakunta Central Hospital, Pori, Finland - pasi.karjalainen@satshp.fi.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Review of clinical data with Paccocath- Coated Balloon Catheters.
Next Document:  Patient selection for MitraClip therapy impaired left ventricular systolic function.